

## **Effects of Age, Sex, Serostatus and Underlying Comorbidities on Humoral Response Post-SARS-CoV-2 Pfizer-BioNTech Vaccination – A Systematic Review**

Kin Israel Notarte<sup>1</sup>, Abbygail Therese Ver<sup>1</sup>, Jacqueline Veronica Velasco<sup>1</sup>, Adriel Pastrana<sup>1</sup>, Jesus Alfonso Catahay<sup>1</sup>, Gian Luca Salvagno<sup>2,3</sup>, Eric Peng Huat Yap<sup>4</sup>, Luis Martinez-Sobrido<sup>5</sup>, Jordi Torrelles<sup>5</sup>, Giuseppe Lippi<sup>3\*</sup>, and Brandon Michael Henry<sup>5,6\*</sup>

<sup>1</sup>Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines

<sup>2</sup>Service of Laboratory Medicine, Pederzoli Hospital, Peschiera del Garda, Italy

<sup>3</sup>Section of Clinical Biochemistry, University of Verona, Verona, Italy

<sup>4</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

<sup>5</sup>Host-Pathogens Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA

<sup>6</sup>Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Ohio, USA

*\*These authors share senior authorship of this manuscript*

*Corresponding Author:*

Brandon Michael Henry, MD

Texas Biomedical Research Institute

8715 W Military Dr.

San Antonio, Texas, USA

*Tel/Fax: 716.598.8610 / Email: [bhenry@txbiomed.org](mailto:bhenry@txbiomed.org)*

## ABSTRACT

With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, several vaccines have been developed to mitigate its spread and prevent adverse consequences of the Coronavirus Disease 2019 (COVID-19). The mRNA technology is an unprecedented vaccine, usually given in two doses to prevent SARS-CoV-2 infections. Despite effectiveness and safety, inter-individual immune response heterogeneity has been observed in recipients of mRNA-based vaccines. As a novel disease, the specific immune response mechanism responsible for warding off COVID-19 remains unclear at this point. However, significant evidence suggests that humoral response plays a crucial role in affording immunoprotection and preventing debilitating sequelae from COVID-19. As such this paper focused on the possible effects of age, sex, serostatus, and comorbidities on humoral response (*i.e.*, total antibodies, IgG and/or IgA) of different populations post-mRNA-based Pfizer-BioNTech vaccination. A systematic search of literature was performed through PubMed, Cochrane CENTRAL, and Google Scholar. Studies were included if they reported humoral response to COVID-19 mRNA vaccines. A total of 32 studies was identified and reviewed, and the percent difference of means of reported antibody levels were calculated for comparison. Findings revealed that older individuals, the male sex, seronegativity, and those with more comorbidities mounted less humoral immune response. Given these findings, several recommendations were proposed regarding the current vaccination practices. These include giving additional doses of vaccination for immunocompromised and elderly populations. Another recommendation is conducting clinical trials in giving a combined scheme of mRNA vaccines, protein vaccines, and vector-based vaccines.

*Keywords: COVID-19, mRNA vaccines, Pfizer-BioNTech, mRNA BNT162b2, immunoglobulins*

## **INTRODUCTION**


Over 200 million infected cases and over 4.6 million Coronavirus Disease 2019 (COVID-19) deaths have been reported globally [1]. The rapid transmissibility of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) including variants being monitored (VBM) and variants of concern (VoC), have sparked fear worldwide and forced many countries to deal with repeated surges in confirmed cases and deaths [2]. To control the pandemic, innovative therapeutic strategies have been formulated, with the specific aim to avert clinical outcomes and limit morbidity, disability, and death associated with COVID-19 [3]. A SARS-CoV-2 vaccination program that is cost-effective, safe, and efficacious is also implemented globally. Among the different types of COVID-19 vaccines, the utilization of a new generation of mRNA-based vaccines is unprecedented, and showed high efficacy to trigger immunoprotective humoral response [4]. Despite their effectiveness in reducing the risk of infection and clinical deterioration, the considerable inter-individual heterogeneity in post-vaccine immune response has been increasingly observed in specific populations, particularly among the elderly and immunocompromised individuals [5,6]. To account for low vaccine responders or individuals with less effective production of neutralizing antibodies, this systematic review is focused on determining the possible effects of age, sex, serostatus, and underlying comorbidities on humoral response of recipients of mRNA-based vaccines.

## **METHODS**

### **Search Strategy and Eligibility Criteria**

A systematic literature search was conducted to identify studies reporting the factors affecting humoral response of individuals who received the mRNA vaccines. As shown in Figure 1, a comprehensive search was carried out in PubMed, Cochrane CENTRAL, and Google Scholar for articles published from January to end of July 2021. The search keywords include “age”, “sex”, “seropositivity”, “comorbidities”, “humoral response”, “mRNA vaccine”, “Pfizer-BioNTech”, and “mRNA BNT162b2” which resulted in 150 journal articles. For the inclusion criteria, articles reporting the following data were considered: (1) total IgG or IgA or neutralizing antibody titers, (2) quantitative antibody tests, (3) mRNA-based vaccines, (4) articles reporting time points for data extraction, (5) articles available in the English language, and (6) randomized controlled,

cohort, preprint or published papers as long as they provide extractable data given the limited papers available for this novel disease and the mRNA vaccine. Exclusion criteria were IgM response and cell-mediated immunity, the former because it is now increasingly clear that IgM plays a minor role against COVID-19 (it does not always appear, wanes very early and has lower neutralizing potential), the latter because we only focused on humoral immunity.



**Figure 1.** Screening and appraisal of journal articles for inclusion in the systematic review.

The search results were tabulated, and duplicates were removed. Full text of each article was retrieved and assessed for final eligibility independently by any two reviewers. Any disagreement was resolved by consensus of all authors.

## Data Extraction

Descriptive and outcome data were extracted from the included studies. The extracted data includes the type of vaccine, country of origin, sample size, age range or median age of the population, type of immunoglobulin measured, and percent mean difference between the control and factors affecting humoral immune response observed in the various studies. Additional data was requested from the original study authors when necessary.

## Data Analysis

Due to significant heterogeneity in the assays used to probe antibody titers, we standardized antibody measurements reported in the articles that were included using a percent difference of means computed using the formula:

$$\text{Percent (\%) Difference of Means} = \left| \frac{(\text{Group A Mean} - \text{Group B Mean})}{\text{Group A Mean}} \right|$$

This enables the comparison of laboratory results regardless of the units of measurements and the diagnostic tools for quantification of antibody titers.

## Scope and Limitations

The demographic parameters used in this study were limited to age, sex, serostatus, and comorbidities such as hemodialysis or end-stage renal disease (ESRD), transplant recipients, and metabolic derangements including obesity, hypertension, and smoking. These factors were analyzed independently of each other, with the exception of concurrent effects of age with comorbidities.

In addition, only Pfizer-BioNTech (mRNA BNT162b2) vaccine was used in this study as it was the leading vaccine utilized worldwide and due to the wide range of available studies at the time of writing. Moreover, the authors utilized both preprint and published journal articles written in the year 2021, with at least a record of 10 patients and above, used mRNA vaccines and quantitative antibody tests, and reported IgG or IgA to determine humoral response. No data on cell mediated immunity was included and all time points shown in the data were in reference to the first dose after vaccine administration.

## RESULTS

A total of 32 articles were included in our analysis. These were divided into four categories, humoral response influenced by (1) age, (2) sex, (3) baseline serostatus (*i.e* seropositive or seronegative), and (4) presence of comorbidities. Seven articles were included under the age category, three under the sex category, 12 under serostatus, and 18 under the comorbidities category. The comorbidity category was further subdivided into four classes: hemodialysis or end stage renal disease (5 articles), cancer and autoimmune diseases (6 articles), transplant patients (4 articles), and metabolic derangements (3 articles). The articles reviewed under each category were non-exclusive, as most studies analyzed their samples with at least two of the mentioned factors.

Tables 1-4 provide a summary of the following trends observed in this study. In general, mRNA vaccines were able to mount efficient antibody responses; however, the level of titers produced varied according to the factors of age, sex, serostatus, and comorbidities. The rate at which antibodies produced decline over time is also influenced by the aforementioned factors. Older individuals, the male sex, seronegativity, and those with more underlying comorbidities mounted less humoral immune response. Aging, in particular, is a significant aggravating factor in the decline of humoral response among recipients with underlying comorbidities, especially when compounded with immunosuppressive medications.

## DISCUSSION

### Factors Affecting Humoral Response

#### Age

A critical factor that makes the elderly more susceptible to infectious diseases is immunosenescence or the decline of immune system functionality as people age [7]. Immunosenescence has been linked with diminished response to vaccination and could therefore influence the success of vaccination [8]. There is clear evidence that the decline in adaptive immunity results in dramatically reduced vaccine responses and vaccine longevity in older adults [7]. This is well-documented with influenza A/H1N1 vaccination, where age negatively correlates with humoral immunity [9,10]. Like any other vaccine, there is accumulating evidence that immunosenescence could also impact the effectiveness of COVID-19 mRNA vaccines, and may hence be less protective to the elderly [11].

Several journal articles reviewed in Table 1, regardless of age stratification, reported that younger individuals developed a greater antibody response after vaccination compared to older individuals [12–17]. Meanwhile, Rios *et al.* reported no association between age and antibody response [5]; however, this article may be limited by the characteristics of its sample size. The study used residents of long-term care facilities, with variable disability and frailty profiles, who had a mean age of 82.9 years, with a range of 65-99 years.

Nevertheless, the findings of most of the studies were consistent with the current knowledge that there is diminished humoral response among the elderly (>65 years), owing to qualitative differences in memory B cells and plasma cells, and expansion of a pro-inflammatory subset of B cells [16]. Elderly individuals were noted to have decreased vaccine-specific antibody titers, and thus were more likely to be non- or low responders [15]. In addition, elderly individuals had more rapidly waning antibody levels [15]. This difference in antibody response was most prominent following the first dose of COVID-19 mRNA, but subsequently decreased over time, especially after the second dose [14,15,17].

Interestingly, the relationship between age and IgG or IgA antibody response was not limited to the elderly. Individuals across all age groups demonstrated this trend. Young individuals (12-64 years) consistently produced increased antibody titers compared to their older counterparts. This difference was even more pronounced between groups with large age gaps, further emphasizing the effect of age on antibody response.

These differences in antibody response have practical implications in COVID-19 vaccination programs. It highlights the importance of a second (or even a third) dose in order to boost the protective response in older individuals [15]. It also highlights the need to individualize vaccination programs and create strategies to account for possible age-related limitations for COVID-19 vaccination [14].

**Table 1.** Effect of age in humoral response following Pfizer-BioNTech (mRNA BNT162b2) vaccine administration.

Author	Vaccine	Country of Origin	Sample Size	Age Range/ Median Age	Measured Immunoglobulin	% Difference of Means
						<b>D21</b>
						IgG titer of participants <30 y/o is 61% higher than ages 30-39 y/o
						IgG titer of participants <30 y/o is 32% higher than ages 40-49 y/o
						IgG titer of participants <30 y/o is 39% higher than ages 50-59 y/o
						IgG titer of participants <30 y/o is 50% higher than ages 60+ y/o
Jabal <i>et al.</i> [13]	Pfizer-BioNtech	Safed, Israel	514	57 y/o (30-60+)	S1/S2 IgG	IgG titer of participants 30-39 y/o is 19% higher than ages 40-49 y/o
						IgG titer of participants 30-39 y/o is 23% higher than ages 50-59 y/o
						IgG titer of participants 30-39 y/o is 41% higher than ages 40-49 y/o
						IgG titer of participants 40-49 y/o is 10% higher than ages 50-59 y/o
						IgG titer of participants 40-49 y/o is 23% higher than ages 60+ y/o
						IgG titer of participants 50-59 y/o is 19% higher than ages 60+ y/o



						<b>D21</b> IgG titer of participants <40 years is 53% higher than >40 years
Naaber <i>et al.</i> [15]	Pfizer-BioNtech	Tartu, Estonia	118	34 y/o (21-68)	S-RBD IgG	<b>D28</b> IgG titer of participants <40 years is 26% higher than >40 years  <b>D63</b> IgG titer of participants <40 years is 27% higher than >40 years
Salvagno <i>et al.</i> [17]	Pfizer-BioNtech	Verona, Italy	925	Mean age (range) <b>Seropositive:</b> 43 y/o (30-56) <b>Seronegative:</b> 44 y/o (31-57)	S-RBD IgG	<b>D21</b> IgG titer is 84% higher in <60 y/o than ≥60 y/o participants  <b>D50</b> IgG titer is 33% higher in <60 y/o than ≥60 y/o participants
Rios <i>et al.</i> [6]	Pfizer-BioNtech	Albacete, Spain	134	<b>Total (n=134):</b> 82.9 y/o (65-99) ≥80 y/o (n=86, [64.2%]) 65-79 y/o (n=48, [35.8%])	S IgG	<b>D43</b> IgG is 28% higher in ≥80 y/o vs 65-79 y/o participants
Pellini <i>et al.</i> [16]	Pfizer-BioNtech	Rome, Italy	248	<b>Total (n=248):</b> 47 y/o (18-75)  ≤37 y/o n=62 37-47 y/o n=63	S1/S2 IgG	<b>D28</b> IgG titer is 27% higher in <37 y/o than 37-47 y/o participants  IgG titer is 47% higher in <37 y/o than 47-56 y/o participants  IgG titer is 60% higher in <37 y/o

				47-56 y/o n=64 >56 y/o n=59		than >56 y/o participants  IgG titer is 28% higher in 37-47 y/o than 47-56 y/o participants  IgG titer is 45% higher in 37-47 y/o than >56 y/o participants  IgG titer is 24% higher in 47-56 y/o than >56 y/o participants
Muller <i>et al.</i> [14]	Pfizer-BioNtech	Cologne, Germany	176	<b>Younger group (&lt;60 y/o): n=91 (53%)</b> Mean age: 42.2 y/o (range: 19.5-59.5)  <b>Elderly group (&gt;80 y/o): n=85 (47%)</b> Mean age: 87.9 y/o (range: 80.1-100.5)	S1 IgG	<b>D17-D19</b> IgG is 87% higher in the younger group than in the elderly group  <b>D38</b> IgG is 64% higher in the younger group than in the elderly group
Frenck <i>et al.</i> [12]	Pfizer-BioNtech	12-15 y/o group from United States  16-25 y/o group from other countries (Argentina, Brazil, Germany, South Africa, Turkey)	3358  <b>Received Pfizer Vaccine n=1668</b> 12-15 y/o n=1131 16-25 y/o n=537  <b>Placebo n=1690</b> 12-15 y/o	<b>Received Pfizer Vaccine</b> <b>12-15 y/o: 14 (12-15)</b> <b>16-25 y/o: 18 (16-25)</b>  <b>Placebo</b> <b>12-15 y/o: 14 (12-15)</b> <b>16-25 y/o: 19 (16-25)</b>	SARS-CoV-2 Serum Neutralization Assay	<b>D49</b> In those without evidence of infection, neutralizing titer is 43% higher in the 12-15 y/o group than the 16-25 y/o group  In all participants regardless of serologic evidence of previous infection who received Pfizer vaccine, neutralizing titer is 43% higher in the 12-15 y/o group than the 16-25 y/o group  In all participants regardless of

---

*n*=1129  
16-25 y/o  
*n*=561

serologic evidence of previous  
infection who received placebo,  
neutralizing titer is 29% higher in  
the 12-15 y/o group than the 16-25  
y/o group

---

*\*ND – No Data*

## Sex

Females develop a greater antibody response due to hormonal differences compared to males, which regulates both adaptive and innate immune responses, with estradiol and testosterone having enhancing and suppressive effects, respectively [19]. However, levels of sex hormones change with age. Thus, after menopause the drop in estradiol levels enhances immunosenescence [19]. Studies in childhood vaccination enables research that focus on sex-dependent response aside from sex hormones that increase after puberty. Such is the case in studies on Measles, Mumps, and Rubella (MMR) and Diphtheria, Pertussis, and Tetanus (DPT) vaccines [20]. These suggest that genetic factors may play a role. The X chromosome expresses more genes, many of which influence immunity. This includes microRNAs (miRNAs) that are known to modulate immunity [20]. Several studies suggest that a similar trend is also observed among COVID-19 mRNA vaccines, noting a higher humoral response and adverse events among women.

Among the articles reviewed in Table 2, two studies showed a direct relationship between sex and humoral response. Both studies by Jabal *et al.* and Pellini *et al.* reported that the female sex is generally superior to male in terms of production of IgG in Day 21 and Day 28 post-vaccination of Pfizer-BioNtech, respectively [13,16]. These data further strengthen the previous studies of Ciarambino *et al.* that female gender has generally decreased susceptibility to viral infections from protection given by X chromosome and/or sex hormones [21]. The X chromosome provides females greater inflammatory, antiviral, and humoral immune responses compared to males. In addition, estrogen, a key hormone in females, plays a significant part in immune regulation.

Furthermore, studies by Ma *et al.* showed that estrogen can directly inhibit SARS-CoV-2 replication by regulating cell metabolism and maintaining cell integrity through genetic modification and improving metabolic function, reducing incidence of SARS-CoV-2 infection [22]. In contrast, testosterone suppresses immune functions by acting on androgen receptors and immune cell activity thereby decreasing inflammation and promoting anti-inflammatory responses. Thus, females have baseline physiologic advantage in mounting immune response than males.

**Table 2.** Effect of sex in humoral response following Pfizer-BioNTech (mRNA BNT162b2) vaccine administration.

Author	Vaccine	Country of Origin	Sample Size	Age Range/ Median Age	Measured Immunoglobulin	% Difference of Means
Salvagno <i>et al.</i> [17]	Pfizer-BioNtech	Verona, Italy	925	<b>Seropositive:</b> Range, 43 +/- 13 years <b>Seronegative:</b> Range, 44 +/- 13 years	S-RBD IgG	<b>D30</b> Among all participants, IgG titer of female participants is 13% higher than males  Among baseline seronegative participants, IgG titer of female participants is 16% higher than males
Pellini <i>et al.</i> [16]	Pfizer-BioNtech	Rome, Italy	248	47 y/o (range 23-69 y/o)	S1/S2 IgG	<b>D28</b> IgG titer of female participants is 37% higher than males
Jabal <i>et al.</i> [13]	Pfizer-BioNtech	Safed, Israel	514	57 y/o (range 30 - 60+)	anti-N IgG	<b>D21</b> IgG titer of female participants is 15% higher than males

\*ND – No Data

## Serostatus

Vaccines act by triggering the body's immune response, leading to development of humoral and cellular immune responses [17]. Several studies provided evidence that individuals previously infected with SARS-CoV-2 develop early antibody responses right after the primary infection, resulting in inter-individual heterogeneity in post-vaccine immune response [23,24]. The preservation of B-cell mediated memory immunity from patient's previous SARS-CoV-2 infection has been theorized to be the primary cause of the boost-like immune response after COVID-19 vaccination in seropositive individuals [13,25].

Publications in Table 3 showed a robust accelerated, humoral immune response after the first vaccine dose. However, results of antibody titers after the second dose displayed different trends. In two separate studies, antibody titers of seropositive individuals are multiple folds higher than those baseline seronegative subjects after the second vaccine dose [17,26]. On the other hand, some publications stated that there is no significant difference between the two groups after the second dose [27,28,29]. As a result, different recommendations can be gathered from different sources. Kelsen *et al.* recommended that subjects with prior COVID-19 may require only a single dose of vaccine [29], and eventually a second dose only when the antibody levels decline significantly (*i.e.*, typically, after 12 months), or in case new VBM and VoC, characterized by the so-called "escape mutations", become endemic. This is in contrast with the recommendation of Demonbreun *et al.* stating that one vaccine is not enough to produce strong protection against SARS-CoV-2 infection among most people previously infected [30]. Demonbreun *et al.* reported that the humoral response of the seropositive group was significantly lower than the response of the PCR (+) group. The study defined the seropositive group based on the presence of anti-RBD IgG antibodies, while participants who tested positive for SARS-CoV-2 on a clinical molecular diagnostic test for acute infection any time prior to vaccination were categorized as recovered COVID-19 under the PCR (+) group [30]. Yan *et al.* elaborated that the difference among anti-SARS-CoV-2 titers may be attributed to the higher initial amounts of viral antigens in cases of severe COVID-19. It may also be the result of an excessive immune response, selective B-cell plasmablast amplification, and enhanced and prolonged B-cell receptor stimulation in patients with severe COVID-19 [31].

Therefore, proper investigation is necessary so that the heightened immune response among seropositive individuals may be used to incite strategic change among vaccine distribution,

promoting faster vaccine dispensing and better vaccine allocation, especially to high-risk populations [32].

**Table 3.** Effect of serostatus in humoral response following Pfizer-BioNTech (mRNA BNT162b2) vaccine administration.

Author	Vaccine	Country of Origin	Sample Size	Age Range/ Median Age	Measured Immunoglobulin	% Difference of Means
Salvagno <i>et al.</i> [17]	Pfizer- BioNtech	Verona, Italy	925	<b>Seropositive:</b> Range, 43 +/- 13 years  <b>Seronegative:</b> Range, 44 +/- 13 years	S-RBD IgG	<b>D21</b> IgG titer of Seropositive participants is 99% higher than seronegative
						<b>D50</b> IgG titer of seropositive participants is 91% higher than seronegative
Kelsen <i>et al.</i> [29]	Pfizer- BioNtech	US, PA	61	<b>Seropositive:</b> 47 years <b>Seronegative:</b> 45 years  <b>age range not reported</b>	S-RBD IgG	<b>D1</b> IgG titer of seropositive participants is 100% higher than seronegative participants
						<b>D14</b> IgG titer of seropositive participants is 95% higher than seronegative participants
						<b>D28</b> No significant difference
						<b>D42</b> No significant difference
Callegaro <i>et al.</i> [26]	Pfizer- BioNtech	Bergamo, Italy	184	<b>Seropositive:</b> 49 y/o (range 43-55)	RBD IgG	<b>D56</b> No significant difference
						<b>D20</b> IgG titer of seropositive



				<b>Seronegative: 51 y/o</b> (range 39.7-56)		participants is 36% higher than seronegative participants"
Efrati <i>et al.</i> [33]	Pfizer-BioNtech	Be'er Ya'akov, Israel	255	18 y/o and older <b>median age not reported</b>	S1 and S2 IgG	<b>D1</b> IgG titer of seropositive participants is 89% higher than seronegative participants <b>D21</b> IgG titer of seropositive participants is 83% higher than seronegative participants
Ebinger <i>et al.</i> [27]	Pfizer-BioNtech	Los Angeles, California	Total: n=1090 Pre-vaccine: n=981 Post-vaccine dose 1: n=525 Post-vaccine dose 2: n=239	Total: 41.89 (12.18) Pre-vaccine: 41.60 (12.05) Post-vaccine dose 1: 43.66 (12.79) Post-vaccine dose 2: 44.12 (12.65)	SARS-CoV-2 IgG	<b>D-1 - D3:</b> Ab titer is 90% higher in participants with previous infection than those without <b>D7 - D21:</b> Ab titer is 30% higher in participants with previous infection than those without <b>D28 - D42:</b> Ab titer is 7% higher in participants with previous infection than those without
Demonbrun <i>et al.</i> [30]	Pfizer-BioNtech Moderna	Chicagoland, Illinois	Total: n=290 PCR (+): n=42 Seropositive: n=105	38 y/o (range 21-83)	S-RBD IgG	<b>D9 (Both Pfizer &amp; Moderna)</b> Ab titer is 92% higher in PCR(+) than seropositive participants Ab titer is 95% higher in PCR(+) than seronegative participants Ab titer is 42% higher in

			Seronegative: $n=143$			seropositive than seronegative participants
						<p><b>D26 (Pfizer) / D33 (Moderna)</b> Ab titer is 37% higher in PCR(+) than seropositive participants</p> <p>Ab titer is 46% higher in PCR(+) than seronegative participants</p> <p>Ab titer is 14% higher in seropositive than seronegative participants</p>
Predeck <i>et al.</i> [34]	Pfizer-BioNtech	London, England	72	ND	S IgG	<p><b>D21-25</b></p> <p>Ab titer is 96% higher in seropositive participants than in seronegative participants</p>
Rios <i>et al.</i> [6]	Pfizer-BioNtech	Albacete, Spain	134	82.9 y/o (range 65-99)	S IgG	<p><b>D0</b></p> <p>Ab titer is 69% higher in seropositive participants than in seronegative participants</p>
Jabal <i>et al.</i> [13]	Pfizer-BioNtech	Safed, Israel	514	57 y/o (range 19-77)	N IgG	<p><b>D28-64: ND</b></p> <p><b>D21</b></p> <p>Geometric mean IgG titer is 89% higher in participants with a (+) PCR test than in participants who are IgG (-) at baseline and no prior positive PCR test.</p>

						<p>Geometric mean IgG titer is 92% higher in participants who are IgG (+) at baseline than participants with IgG (-) at baseline and no prior positive PCR test.</p> <p>Geometric mean IgG titer is 88% higher in participants who are IgG (-) with prior (+) PCR test than in participants who are IgG (-) at baseline and no prior positive PCR test.</p>
Padoan <i>et al.</i> [28]	Pfizer- BioNtech	Padova, Italy	163	42.4 y/o, SD = 11.7 y/o	S-RBD IgG	<p><b>The estimated mean cannot be computed since no sample size was given per group and per time point.</b></p> <p><b>D7</b> Ab titer is 99% higher in seropositive participants than in seronegative participants</p> <p><b>D10</b> Ab titer is 99% higher in seropositive participants than in seronegative participants</p> <p><b>D14</b> Ab titer is 99% higher in seropositive participants than in seronegative participants</p> <p><b>D21</b></p>
Favresse <i>et al.</i> [25]	Pfizer- BioNtech	Belgium	231	<p><b>Female</b> 42.6 y/o (range 23-66)</p> <p><b>Male</b> 42.8 y/o (range 23-64)</p>	NCP IgG S1 IgG	<p><b>D10</b> Ab titer is 99% higher in seropositive participants than in seronegative participants</p> <p><b>D14</b> Ab titer is 99% higher in seropositive participants than in seronegative participants</p> <p><b>D21</b></p>

					Ab titer is 99% higher in seropositive participants than in seronegative participants
					<b>D28</b> Ab titer is 89% higher in seropositive participants than in seronegative participants
					Ab titer is 91% higher in vaccinated participants without previous SARS-CoV-2 infection than in non-vaccinated participants who recovered from COVID-19.
Sasso <i>et al.</i> [35]	Pfizer-BioNtech	Palermo, Italy	2607	<b>Vaccinated</b> = 57 y/o (41-65) <b>Recovered</b> = 51 y/o (36-56) <b>COVID-19 recovered</b> = 56 y/o (47-63)	S-RBD IgG Ab titer is 89% higher in vaccinated participants who recovered from COVID-19 than in non-vaccinated participants who recovered from COVID-19. Ab titer is 14% higher in vaccinated participants without previous SARS-CoV-2 infection than in vaccinated participants who recovered from COVID-19.

\*ND – No Data

## Comorbidities

The presence of comorbidities, such as chronic kidney diseases (CKD), diabetes mellitus (DM) and cardiovascular disease (CVD), are clinical risk factors significantly associated with poorer prognosis in patients with COVID-19 [34]. This is greatly attributed to the disease mechanisms resulting in metabolic disorders that impair lymphocyte and macrophage functions, hence also negatively affecting the immune response after COVID-19 vaccination [37,38]. To highlight the effect of comorbidities in humoral response of individuals receiving the COVID-19 mRNA vaccine, Rios *et al.* reported that immune response in the elderly with higher number of comorbidities is blunted by 30% as compared to those with lesser comorbidities [6]. Thus, the high prevalence of people with comorbidities, combined with increasing age (>60 years) as seen in Table 4, shows that the presence of both factors may aggravate the already blunted response in affected individuals, as aging accelerates the rapid decline in humoral immunity. [39]. The following sections outline the different comorbidities that may affect humoral response following COVID-19 mRNA vaccination, as highlighted in Table 4.

### *Hemodialysis or End Stage Renal Disease*

Hemodialysis patients (HDP) have been identified to be at high-risk of acquiring severe COVID-19 associated symptoms [40]. Most of these patients develop uremia, resulting in ineffective leukocyte function, decreased antigen processing and presentation, and subsequently disrupted innate and adaptive immune responses [41]. In the event of getting infected, these patients cannot fully observe quarantine protocols because of their dependencies on dialysis treatments [42]. Studies have shown that vaccination is the most cost- and resource-effective preventive measure available [43]. We tackled herewith the immunological response of hemodialysis patients to mRNA vaccines.

Among five publications that discussed HDP, only two studies compared HDP to control, and both presented consistent findings that the control group had higher immune responses compared to hemodialysis subjects [43,44]. Nonetheless, all five studies reported a response in majority of their subjects after two doses of the vaccination. Frantzen *et al.* noted that the results go far beyond the hyporesponsive population [45].

Furthermore, Jahn *et al.* reported that HDPs under the age of 60 years responded equally to the control group [43]. However, a limitation of the study was the lack of control subjects over the age of 60 years. In a study by Torreggiani *et al.*, it was found that younger HDPs ( $62.31 \pm 16.20$  years) with lower comorbidity burden are more likely to mount an antibody response and have higher response compared to older patients ( $73.72 \pm 11.18$ ) with more comorbidity burden [44]. This is consistent with the findings of Jahn *et al.* comparing the humoral response of HDPs across different age ranges as presented in Table 4 [43]. Torreggiani *et al.* raised concerns that after the first vaccination only a third of the HDP patients mounted an immune response [46]. Goupil *et al.* also stated that a single dose failed to elicit humoral response among HDP participants with previous SARS-CoV-2 infection and was delayed even in those previously infected [44]. Nevertheless, Goupil *et al.* noted that previously infected patients had higher response compared to the other HDPs.

Overall, there are concerns on lower vaccine efficacy and shorter period of immunoprotection for HDP patients. Suggestions on adjusting the dosage for this group, especially in the elderly population were recommended in all studies.

### ***Transplant Recipients***

Transplant recipients are at high risk of infection resulting from immunosuppression necessary to prevent organ rejection compounded by immunosuppressive effects of organ failure and chronic disease [47]. Although vaccination has been used as a strategy to prevent infection among transplant recipients, there have been concerns that vaccination may trigger development of donor-specific anti-human leukocyte (HLA) antibodies (DSA) and/or allograft rejection [48,49].

It is thought that vaccination could trigger T- and B-cell responses to vaccine antigens that directly cross-react with alloantigens as in the case of viral infections [50,51]. Furthermore, vaccination can induce cytokine release that may stimulate previously quiescent alloreactive memory responses [50,51]. Adjuvants in vaccines can also lead to non-specific immunostimulating effects that could increase rates of rejection and DSA formation [48,49].

In line with the current pandemic, transplant recipients are a vulnerable group at higher risk for SARS-CoV-2 infection with poorer associated outcomes [52]. The US Centers for Disease

Control and Prevention (CDC&P) outlined the safety of the Pfizer-BioNTech and Moderna vaccines because neither vaccine contains live virus that could be dangerous to immunocompromised patients [53]. In this section, we described humoral responses of transplant recipients who have received the mRNA vaccine

Almost all of the studies reviewed had a mean difference of 90% between transplant recipients and control groups. This is because of blunted immune response of transplant patients most likely due to taking immunosuppressive medications. While antibody titers may develop, these usually develop late, are below the protective threshold, and unfortunately wane faster [54,55]. The observed failure to mount appreciable antibody immune response of transplant recipients is consistent in previous findings exploring other common vaccines [56]. Identified contributors to mount a response includes advanced age, need for high dose of corticosteroids during the past 12 months, maintenance with three immunosuppressive medications, and a regimen that includes mycophenolate, antimetabolites or mTOR inhibitors [56].

Korth *et al.* proposed that novel vaccination strategies may be needed to address this failure [57]. This could either indicate more than two booster doses or a combined scheme with mRNA vaccines, protein/subunit vaccines, and vector-based vaccines. Strict evaluation may also be needed after vaccination in the long-term to learn more about the response of this population.

### ***Cancer and Autoimmune Disease***

Cancer, as a systemic disease, induces functional and compositional changes to the immune system [58]. Some of these changes allow cancer cells to avoid destruction by the immune attack and even support its growth. Studies indicate that B cells responsible for mediating humoral immune response promote and support tumor growth [59]. Depending on the type of cancer, the immunosuppressive tumor microenvironment may vary [60]. In addition, immunosuppression observed among cancer patients may be attributed to their treatment. Similar to the type of cancer, different types of treatment cause different levels of immunosuppression [60]. In a recent study, a significant portion of patients with cancer developed proper humoral immune responses after vaccination [61]. However, recent chemotherapy treatment may be associated with low serologic response [61]. Similar findings were noted on influenza vaccinated patients undergoing chemotherapy compared to healthy controls [62]. Cancer patients who were vaccinated during the early chemotherapy cycle also had better response compared to those in the latter cycle of the

treatment [62]. The possible immunosuppression in cancer patients receiving the Pfizer-BioNTech mRNA vaccine was documented by Herishanu *et al.*, wherein IgG titer among patients diagnosed with chronic lymphocytic leukemia (CLL) was blunted by 80.65% as compared to controls [63]. Moreover, the same pattern of immunosuppression was reported by Massarweh *et al.* wherein the IgG titer of the control group was 68.48% higher than in cancer patients [64]. Furthermore, similar observations were noted by Pimpinelli *et al.* in myeloproliferative malignancies (MPM) and multiple myeloma (MM) [65]. Response in MPM patients was robust, while MM patients had significantly less response. MM patients undergoing regimens without daratumumab were associated with higher adaptive immune responses. This may be due to daratumumab's mechanism of action that targets CD38 on the population of normal and tumor plasma cells, thus reducing vaccine immunogenicity by direct depletion of antibody producer cells. Nonetheless, Goshen-lago *et al.* noted that while there was a pronounced lag in antibody production in cancer cases, seroconversion occurred in most patients after the second dose [66].

An autoimmune disease is a condition arising from an abnormal immune system response which mistakenly attacks healthy cells, tissues, and organs. This immune malfunction can affect any part of the body, weakening bodily function that can be potentially fatal [67]. The cornerstone to management of autoimmune disorders is the use of immunosuppressive therapies. However, various immunosuppressive treatments could impact vaccine-induced immunogenicity [68]. For instance, Gallo *et al.* reported that the geometric mean IgG titer of patients with multiple sclerosis (pwMS) treated with ocrelizumab is 97% lower than healthy participants [69]. However, this study is limited by the small number of tested patients and the inability to assess their cell-mediated and innate immune responses. Larger studies exploring the response to SARS-CoV-2 vaccines in pwMS treated with anti-CD20 drugs (*e.g.*, rituximab) and other high efficacy disease-modifying therapies (DMTs) are necessary to confirm and expand these preliminary data.

Similarly, Furer *et al.* reported an anti-SARS-CoV-2 S1/S2 IgG titer that was 39% lower among participants diagnosed with autoimmune inflammatory rheumatic diseases (AIIRD) as compared to healthy controls [70]. In addition, age could have also been a confounding factor that affected the reported results in this study since majority of the AIIRD participants were elderly with a mean age of 59 years compared to the general population control group with a mean age of 50 years. Among the AIIRDs, rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and idiopathic inflammatory myositis (IIM) were



associated with a low humoral response to the vaccine which may be partially attributed to their underlying treatment. Furthermore, data presented in this study also have important implications for the management of anti-COVID-19 vaccination in patients with a wide spectrum of AIIRD. Most immunosuppressive treatments, including conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), anticytokine, biologics, and janus kinase inhibitors (JAKi), can be safely continued without significantly attenuating vaccine-induced immunogenicity. In contrast to the recommendation of the American College of Rheumatology, this study does not support withholding methotrexate (MTX) and JAKi in relation to COVID-19 vaccination. Meanwhile, treatment with glucocorticoids, rituximab, abatacept in combination with MTX and mycophenolate mofetil was associated with significantly decreased vaccine-induced immunogenicity. Therefore, timing of vaccination has a critical role in these cases. If clinically feasible, postponing administration of rituximab and abatacept, especially when combined with MTX, seems reasonable to improve vaccine-induced immunogenicity.

### ***Metabolic Derangements & Smoking***

Metabolic derangement is an important and prevalent comorbidity to consider. Most of which are associated with high body mass index (BMI) and thus, obesity. Recent studies have highlighted the effect of metabolic syndromes on immunity and pathogen defense and coordination of innate and adaptive responses [71]. These changes are associated with decreased immunity from infection, higher risk for complications, and higher rates of vaccine failure [71]. In a study by Sheridan *et al.*, BMI values correlated positively with higher initial fold increase in IgG antibodies detected after trivalent influenza vaccine [72]. However, 12 months after vaccination, subjects with higher BMI noted a greater decline in antibody titers. The findings on vaccine failure in relation to BMI and obesity are also noted with mRNA-based vaccines [71]. For instance, Pellini *et al.* reported that there is higher anti-spike S1/S2 IgG production in individuals with lower BMI (BMI <18.5) as compared to pre-obese (BMI 25.0-29.9) or obese (BMI >30.0) participants receiving the Pfizer anti-COVID-19 mRNA vaccine [16]. Furthermore, anti-spike immunoglobulin production was 71% higher in non-dyslipidemic than dyslipidemic participants vaccinated with the Pfizer mRNA [73]. This may be correlated to adipokines, cytokine-like hormones released by adipose tissues that bridge cellular metabolism to immune responses. In particular, leptin plays an important role in controlling the interplay between cellular energy

metabolism and regulation of metabolic-immune responses. Indeed, leptin plays a role in modulating cell proliferation, responsiveness, and polarization of T cells. Conversely, leptin promotes B cell homeostasis through inhibition of apoptosis and induction of cell entry. Central leptin resistance is the main risk factor for obesity-related acute and chronic diseases. It also plays a role in dysglycemia, particularly in Type 2 diabetes mellitus as leptin is a therapeutic target for its impact on food intake, body weight and potential to improve insulin action [74].

Hypertension is related to impaired metabolic homeostasis, thus is also regarded as a metabolic disorder [75]. It is important to note that the immune and autonomic systems play an important role in the cause of hypertension and other cardiovascular pathologies [76]. The blunted serologic response noted among hypertensive patients may actually be rooted in a dysfunctional immune system [73]. Both Pellini *et al.* and Watanabe *et al.* reported that IgG production against SARS-CoV-2 in normotensive individuals receiving the mRNA vaccine is significantly higher than in hypertensive participants [16,73].

In addition, ample evidence indicates that cigarette smoking could also affect both innate and adaptive immunity [77]. Cigarette smoking is known to attenuate the normal defensive function of the immune system by affecting the nuclear factor-kappa B (NF- $\kappa$ B) and mitogen-activated protein kinases (MAPKs) signaling, as well as histone modification epigenetics [77]. As reported by Watanabe *et al.*, the humoral response of smokers who received the mRNA vaccine was blunted by 43% as compared to non-smokers [73]. Based on these studies, it is increasingly clear that suboptimal metabolic health and unhealthy lifestyle practices are associated with poor vaccine-induced immunogenicity.

**Table 4.** Effect of comorbidities in humoral response following Pfizer-BioNTech (mRNA BNT162b2) vaccine administration.

Author	Vaccine	Country of Origin	Sample Size	Age Range/ Median Age	Measured Immunoglobulin	% Difference of Means	
<b>Hemodialysis / End Stage Renal Disease</b>							
Jahn <i>et al.</i> [43]	Pfizer-BioNtech	Germany	88	<p><b>Controls</b> (<i>n</i>=16) <b>Hemodialysis patients (HDP)</b> (<i>n</i>=72) none had immunosuppressive medication</p> <p><b>Median time on dialysis (Q1;Q3):</b> 52 months (24.5; 111.7)</p>	<p><b>Controls:</b> 45.5 y/o (39-65)</p> <p><b>HDP:</b> 68 y/o (37-90) 37–59 y/o (<i>n</i>=17): 54 y/o 60–69 y/o (<i>n</i>=22): 64.5 y/o 70–79 y/o (<i>n</i>=22): 76 y/o 80–90 y/o (<i>n</i>=11): 82 y/o</p>	SARS-CoV-2 IgG	<p><b>D38</b> Ab is 44% higher in HCW than all HDP</p> <p><b>HCW vs 37-59 y/o HDP</b> Ab is 21% higher in HCW than 37-59 y/o HDP</p> <p><b>HCW vs 60-69 y/o HDP</b> Ab is 40% higher in HCW than 60-69 y/o HDP</p> <p><b>HCW vs 70-79 y/o HDP</b> Ab is 62% higher in HCW than 70-79 y/o HDP</p> <p><b>HCW vs 80-90 y/o HDP</b> Ab is 66% higher in HCW than 80-90 y/o HDP</p> <p><b>37-59 y/o HDP vs 60-69 y/o HDP</b> Ab is 24% higher in 37-59 y/o HDP than 60-69 y/o HDP</p> <p><b>37-59 y/o HDP vs 70-79 y/o HDP</b> Ab is 52% higher in 37-59 y/o HDP than 70-79 y/o HDP</p> <p><b>37-59 y/o HDP vs 80-90 y/o HDP</b></p>

			Ab is 57% higher in 37-59 y/o HDP than 80-90 y/o HDP
			<b>60-69 y/o HDP vs 70-79 y/o HDP</b> Ab is 37% higher in 60-69 y/o HDP than 70-79 y/o HDP
			<b>60-69 y/o HDP vs 80-90 y/o HDP</b> Ab is 43% higher in 60-69 y/o HDP than 80-90 y/o HDP
			<b>70-79 y/o HDP vs 80-90 y/o HDP</b> Ab is 9% higher in 70-79 y/o HDP than 80-90 y/o HDP
Goupil <i>et al.</i> [44]	Pfizer- BioNtech	Canada	<p><b>Control</b> (<i>n</i>=40) w/o prev SARS-CoV 2 infection mean ± SD: 47 ± 12 median: 52, (range 21–59)</p> <p><b>Hemodialysis patients(HDP)</b> (<i>n</i>=150) w/o prev SARS-CoV 2 infection (<i>n</i>=131) w/ prev SARS-CoV 2 infection (<i>n</i>=19)</p> <p><b>Control</b> (<i>n</i>=40) w/ prev SARS-CoV 2 infection (<i>n</i>=20) mean ± SD: 47 ± 13 median: 46, (range 23–65)</p> <p><b>Hemodialysis patients(HDP)</b> (<i>n</i>=150) w/o prev SARS-CoV 2 infection (<i>n</i>=131) w/ prev SARS-CoV 2 infection (<i>n</i>=19) mean ± SD: 70 ± 14 median: 73, (range</p> <p>Anti-N</p>
			<b>D21</b> <b>Controls</b> IgG is 81% higher in those with previous infection than those without previous infection
			<b>D26</b> <b>HDP</b> IgG is 95% higher in those with previous infection than those without previous infection
			<b>D56</b> <b>HDP</b> IgG is 96% higher in those with previous infection than those without previous infection
			<b>D21 and D26</b>

				33–92) w/ prev SARS-CoV 2 infection ( $n=19$ ) mean $\pm$ SD: $76 \pm 12$ median: 76, (range 51–90)		<b>Without previous infection, controls vs HDP</b> IgG is 89% higher in those controls without previous infection than HDP without previous infection
						<b>With previous infection, controls vs HDP</b> IgG is 60% higher in those controls with previous infection than HDP with previous infection
Frantzen <i>et al.</i> [45]	Pfizer- BioNtech	France	HDP ( $n=244$ )	Mean 71y/o (range: 63-80)	Anti-S	<b>No control</b>
Zitt <i>et al.</i> [78]	Pfizer- BioNtech	Austria	$n = 50$ Received the first dose $n = 48$ Received the second dose	67.6 y/o	RBD and NTD IgG	<b>No control</b>
Torregiani <i>et al.</i> [46]	Pfizer- BioNtech	Paris, France	101	$68.89 \pm 14.86$	S IgG	<b>No control</b>
<b>Cancer and Autoimmune Diseases</b>						
Herishanu <i>et al.</i> [63]	Pfizer- BioNtech	Israel	<b>219</b> <b>CLL/SLL</b> <b>(<math>n=167</math>)</b> only $n=52$ of patients were	<b>Control (<math>n=52</math>)</b> median age 68 years; (range: 64-74 years) <b>CLL/SLL (<math>n=167</math>)</b>		<b>D35-42</b> The IgG titer of the control is 80.65% higher than the CLL patients"

			compared to control CLL w/ antibody response (n=52)	Age, median median age 71.0 (range: 63.0-76.0)		
			Control (n=52)	≤65 y/o (n=50 [29.9%])		
Pimpinel li <i>et al.</i> [65]	Pfizer- BioNtech	Italy	<b>Control (n=36)</b> elderly subjects over 80 aged not suffering from cancer	over 80 y/o	S1/S2 IgG	Control vs Multiple Myeloma (MM) D21: IgG titer of control is 56% higher than MM patients D35: 69.8%  Control vs Myeloproliferative Malignant Myeloma (MPM) D21: 5.26% D35: 51.06%
Massarweh <i>et al.</i> [64]	Pfizer- BioNtech	Israel	<b>Control (n=78)</b> <b>Solid tumor patients undergoing active IV anticancer treatment (n=102)</b>	<b>Control (n=78)</b> 62 (49-70) <b>Solid tumor patients undergoing active IV anticancer treatment (n=102)</b> 66 (56-72)	S-RBD IgG	<b>D59-61</b> IgG titer of control is 68.48% higher than cancer patients
Goshenlago <i>et al.</i> [66]	Pfizer- BioNtech	Haifa, Israel	<b>Controls (n=261)</b> 118 men (45%), 143 women (55%)	<b>Controls:</b> 64 y/o (range, 25-81) <b>With solid tumors, receiving active</b>	S1/S2 IgG	<b>Mean difference could not be computed</b>

---

**With solid tumors, receiving active intravenous treatment (n=232)**  
132 men (57%),  
100 women (43%)

**intravenous treatment:**  
68 y/o (range, 25-88)

**Types of Solid Tumors:**

Gastrointestinal  
(n=63 [27%])

Genitourinary  
(n=48 [21%])

Lung (n=45  
[19%])

Breast (n=42  
[18%]).

Head and neck  
(n=11 [5%])

Gynecologic  
(n=11 [5%])

Melanoma (n=5  
[2%])

Neurologic (n=5  
[2%])

Sarcoma (n=2  
[1%])

---

			<b>Stage:</b> Local ( $n=60$ [26%]) Metastatic ( $n=172$ [74%])
			<b>Treatment:</b> Chemotherapy ( $n=134$ [58%]) Biological agent ( $n=81$ [35%]) Immunotherapy ( $n=83$ [36%])
			<b>General population control</b> ( $n=121$ )
			<b>Control</b> 50 y/o (range 18-90)
			<b>AIIRD</b> 59 y/o (range 19-88)
			<b>Autoimmune inflammatory rheumatic diseases (AIIRD)</b> ( $n=686$ )
			RA: 64 y/o (range 20-88)
			PsA: 55 y/o (range 20-86)
			Rheumatoid arthritis (RA) ( $n=263$ )
			AxSpA: 49.5 y/o (range 21-83)
			Psoriatic arthritis (PsA) ( $n=165$ )
			SLE: 46 y/o (range 22-80)
			Axial spondyloarthritis
			IIM: 64 y/o (range 34-76)
			<b>D45-D63</b>
			Ab titer is 39% higher in controls than participants with autoimmune inflammatory rheumatic diseases
			Ab titer is 50% higher in controls than participants with rheumatoid arthritis
			Ab titer is 26% higher in controls than participants with psoriatic arthritis
			Ab titer is 21% higher in controls than participants with axial spondyloarthritis
			Ab titer is 26% higher in controls
Furer <i>et al.</i> [70]	Pfizer-BioNtech	Israel	S1/S2 IgG



		(AxSpA) ( <i>n</i> =68)		than participants with systemic lupus erythematosus
		Systemic lupus erythematosus (SLE) ( <i>n</i> =101)	LVV: 70 y/o (range 26-85)	Ab titer is 80% higher in controls than participants with idiopathic inflammatory myositis
		Idiopathic inflammatory myositis (IIM) ( <i>n</i> =19)	AAV: 60.5 y/o (range 26-85)	Ab titer is 34% higher in controls than participants with large vessel vasculitis
		Large vessel vasculitis (LVV) ( <i>n</i> =21)	Other vasculitis: 56 y/o (19-77)	Ab titer is 82% higher in controls than participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
		Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) ( <i>n</i> =26)		Ab titer is 44% higher in controls than participants with other types of vasculitis
		Other vasculitis ( <i>n</i> =23)		
Gallo <i>et al.</i> [69]	Pfizer-BioNtech	Italy	<b>Healthcare workers</b> ( <i>n</i> =121)	<b>D14:</b> Geometric mean IgG titer is 92% higher in healthcare worker controls than patients with multiple sclerosis
			<b>Healthcare workers</b> 41.2 y/o (range 31.9-55.9)	
			<b>People with multiple sclerosis (pwMS) on</b>	<b>D21:</b> Geometric mean IgG titer is 90% higher in healthcare worker controls than patients with
			Patient 1: 33 y/o	
			Patient 2: 35 y/o	

			<b>ocrelizumab (OCR) (n=4)</b>	Patient 3: 42 y/o Patient 4: 51 y/o		multiple sclerosis  <b>D28:</b> Geometric mean IgG titer is 97% higher in healthcare worker controls than patients with multiple sclerosis
--	--	--	--------------------------------	--	--	--

### Transplant Patients

Korth <i>et al.</i> [57]	Pfizer-BioNtech	Germany	Control HCW (n=23)  Renal transplant patients (n=23)	Control mean age was 44.4 +/- 9.2 y/o  Renal transplant patient mean age was 57.7 +/- 13.5 y/o	anti-SARS-CoV-2 IgG	The IgG titer of control is 92.9% higher than renal transplant patients
Marinaki <i>et al.</i> [53]	Pfizer-BioNtech	Greece	Control HCW (n=116)  Solid organ transplant (SOT) (n=34)	Control HCW (n=116) age matched but none mentioned  Solid organ transplant (SOT) (n=34) ≤60 n=17 >60 n=17	anti-SARS-CoV-2-RBD IgG a	Antibody response rate of Control is 41.2% higher than solid organ transplants
Shostak <i>et al.</i> [55]	Pfizer-BioNtech	Israel	168	n = 168 60.5 (49.25-67.75)	SARSCoV-2 IgG II	<b>D22-28</b> IgG titers of previous seropositive individuals is 81.97% higher than seronegative individuals  <b>D35-42</b>

						IgG titers of previous Seropositive individuals is 99.07% higher than seronegative individuals
Grupper <i>et al.</i> [56]	Pfizer-BioNtech		HCW (n=25) Kidney transplant patients (n=136)	HCW (n=25) mean: 52.7  Kidney transplant patients (n=136) mean: 58.6	SARS-CoV-2 S1/S2 IgG	IgG titer of control group is 92.49% higher than kidney transplant group
<b>Metabolic Derangements</b>						
Rios <i>et al.</i> [6]	Pfizer-BioNtech	Albacete, Spain	134	82.9 y/o (range 65-99)	S-RBD IgG	<b>D43:</b> IgG titer of participants with Charlson index < 3 is 30% less than those with Charlson index > / = 3
						<b>D28</b>
						Ab GMC is 28% higher in underweight than normal weight participants
Pellini <i>et al.</i> [16]	Pfizer-BioNtech	Rome, Italy	248	47 y/o (range 18-75)	S1/S2 IgG	Ab GMC is 51% higher in underweight than pre-obese individuals
						Ab GMC is 63% higher in underweight than obese individuals
						Ab GMC is 32% higher in normal weight than pre-obese individuals
						Ab GMC is 49% higher in normal

---

weight than obese individuals

Ab GMC is 25% higher in pre-obese than obese individuals

Ab GMC is 44% higher in normotensive than hypertensive individuals

---

**D28-56**

Ab titer is 43% higher in non-smokers than smokers

Watanabe *et al.* [73] Pfizer-BioNtech Rome, Italy 86 29 y/o S Total Ab

Ab titer is 66% higher in normotensive than hypertensive participants

Ab titer is 71% higher in non-dyslipidemic than dyslipidemic participants

---

*\*ND – No Data, HDP – Hemodialysis patients, HCW – healthcare workers, CLL – chronic lymphocytic leukemia, SLL – Small lymphocytic leukemia, MM – Multiple myeloma, MPM – Myeloproliferative malignant myeloma, AIIRD - Autoimmune inflammatory rheumatic diseases, RA - Rheumatoid arthritis, PsA - Psoriatic arthritis, AxSpA - Axial spondyloarthritis, SLE - Systemic lupus erythematosus, IIM - Idiopathic inflammatory myositis, LVV - Large vessel vasculitis, ANCA- AAV - Antineutrophil cytoplasmic antibody-associated vasculitis, pwMS - people with multiple sclerosis, SOT – Solid organ transplant, GMC – Geometric mean concentration*

## Conclusion

Humoral immune response differs in every individual and is affected by many factors such as age, sex, serostatus, and underlying comorbidities. This systematic review showed that old individuals (>65 years) produce lower anti-SARS-CoV-2 antibody levels and had higher chances to be low- or non-responders, especially when combined with other comorbidities. Interestingly, the female sex has greater antibody production due to the immunomodulating properties of estrogen and the X chromosome. Moreover, due to early antibody response present among seropositive individuals, higher levels of antibodies were measured post-vaccination than seronegative individuals. Presence of comorbidities also showed significant decline in antibody production especially if present in the elderly population. Hemodialysis, transplantation, cancer and autoimmune diseases, as well as metabolic derangements, all shared a blunted humoral immune response which could be rooted to dysfunctional immune system and several factors such as aging, which serves as a significant aggravating factor, as well as the use of immunosuppressive and antimetabolite medications. Hence, further studies in improving vaccination strategies for COVID-19 should be employed in consideration of the aforementioned factors.

It is worth mentioning that additional mRNA-based vaccine boosters have already been attempted in some of these populations of low responders. While presenting a relatively safe reactogenic response comparable to that seen after the first or second mRNA vaccine dose [79], the third vaccine dose was found to be effective in further boosting antibody levels in elderly people [80], in solid organ transplant recipients [81], and in patients receiving maintenance hemodialysis or peritoneal dialysis [82]. The third dose was also effective in reinforcing immunity against VoC [83]. Irrespective of the demographical or clinical conditions that would blunt the anti-SARS-CoV-2 antibody response, the importance of monitoring humoral immunity seems almost unquestionable for prioritizing vaccine boosters, including new vaccines able to efficiently protect against current and potentially future SARS-CoV-2 drifted VoC. Their administration could provide the best compromise between the still limited availability and the highest clinical efficacy in averting or limiting COVID-19 infections and/or severe illness in especially vulnerable populations [84].

## Recommendations

For future researchers it is recommended to investigate further on the correlation and interdependence after combining age, sex, serostatus, and comorbidities and their effect on humoral response. In addition, comparison between other SARS-CoV-2 mRNA vaccines such as Moderna (mRNA 1273) with Pfizer-BioNTech (mRNA BNT162b2) could also be explored using these demographic parameters.

## Disclosure Statement

The authors report no conflict of interest.

## References

- [1] Coronavirus Resource Center. COVID-19 Dashboard <https://coronavirus.jhu.edu/map.html?fbclid=IwAR3YAUh1zt-Y0G1gUqLxByXPQuI1PzhQItISdwOYNgRR0om-BjGOv6Ya-0> (accessed Sep 19, 2021).
- [2] Koyama, T.; Weeraratne, D.; Snowdon, J. L.; Parida, L. Emergence of Drift Variants That May Affect COVID-19 Vaccine Development. *Pathogens*, **2020**, No. 2020, 1–7.
- [3] Lippi, G.; Sanchis-Gomar, F.; Henry, B. M. COVID-19: Unravelling the Clinical Progression of Nature’s Virtually Perfect Biological Weapon. *Ann. Transl. Med.*, **2020**, *8* (11), 693–693. <https://doi.org/10.21037/atm-20-3989>.
- [4] Dolgin, E. How COVID Unlocked the Power of MRNA. *Nature*, **2021**, *589*, 189–191.
- [5] Salmerón Ríos, S.; Mas Romero, M.; Cortés Zamora, E. B.; Taberero Sahuquillo, M. T.; Romero Rizos, L.; Sánchez-Jurado, P. M.; Sánchez-Nievas, G.; Señalada, J. J. B.; García Noguera, I.; Estrella Cazalla, J. de D.; *et al.* Immunogenicity of the BNT162b2 Vaccine in Frail or Disabled Nursing Home Residents: COVID-A Study. *J. Am. Geriatr. Soc.*, **2021**, *69* (6), 1441–1447. <https://doi.org/10.1111/jgs.17153>.
- [6] Geisen, U. M.; Berner, D. K.; Tran, F.; Sümbül, M.; Vullriede, L.; Ciripoi, M.; Reid, H. M.; Schaffarzyk, A.; Longardt, A. C.; Franzenburg, J.; *et al.* Immunogenicity and Safety of Anti-SARS-CoV-2 MRNA Vaccines in Patients with Chronic Inflammatory Conditions and Immunosuppressive Therapy in a Monocentric Cohort. *Ann. Rheum. Dis.*, **2021**, No. Cid, 1–6. <https://doi.org/10.1136/annrheumdis-2021-220272>.
- [7] Lord, J. M. The Effect of Aging of the Immune System on Vaccination Responses. *Hum. Vaccines Immunother.*, **2013**, *9* (6), 1364–1367. <https://doi.org/10.4161/hv.24696>.
- [8] Allen, J. C.; Toapanta, F. R.; Chen, W.; Tennant, S. M. Understanding Immunosenescence and Its Impact on Vaccination of Older Adults. *Vaccine*, **2020**, *38* (52), 8264–8272. <https://doi.org/10.1016/j.vaccine.2020.11.002>.
- [9] Olafsdottir, T. A.; Alexandersson, K. F.; Sveinbjornsson, G.; Lapini, G.; Palladino, L.; Montomoli, E.; Del Giudice, G.; Gudbjartsson, D. F.; Jonsdottir, I. Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population Whereas Disease and Medication Have Small Effects. *Front.*

- Immunol.*, **2018**, *8* (DEC). <https://doi.org/10.3389/fimmu.2017.01872>.
- [10] Haralambieva, I. H.; Painter, S. D.; Kennedy, R. B.; Ovsyannikova, I. G.; Lambert, N. D.; Goergen, K. M.; Oberg, A. L.; Poland, G. A. The Impact of Immunosenescence on Humoral Immune Response Variation after Influenza A/H1N1 Vaccination in Older Subjects. *PLoS One*, **2015**, *10* (3), e0122282. <https://doi.org/10.1371/JOURNAL.PONE.0122282>.
- [11] Bartleson, J.M.; Radenkovic, D.; Covarrubias, A.J.; Furman, D.; Winer, D. A.; Verdin, E.. SARS-CoV-2, COVID-19 and the aging immune system. *Nat Aging* **1**. 2021. 769–782. <https://doi.org/10.1038/s43587-021-00114-7>
- [12] Frenck, R. W.; Klein, N. P.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; Perez, J. L.; Walter, E. B.; Senders, S.; Bailey, R.; *et al.* Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *N. Engl. J. Med.*, **2021**, *385* (3), 239–250. <https://doi.org/10.1056/nejmoa2107456>.
- [13] Jabal, K. A.; Ben-Amram, H.; Beiruti, K.; Batheesh, Y.; Sussan, C.; Zarka, S.; Edelstein, M. Impact of Age, Ethnicity, Sex and Prior Infection Status on Immunogenicity Following a Single Dose of the BNT162b2 MRNA COVID-19 Vaccine: Real-World Evidence from Healthcare Workers, Israel, December 2020 to January 2021. *Eurosurveillance*, **2021**, *26* (6). <https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096>.
- [14] Müller, L.; Andrée, M.; Moskorz, W.; Drexler, I.; Walotka, L.; Grothmann, R.; Ptok, J.; Hillebrandt, J.; Ritchie, A.; Rabl, D.; *et al.* Age-Dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. *Clin. Infect. Dis.*, **2021**. <https://doi.org/10.1093/cid/ciab381>.
- [15] Naaber, P.; Jürjenson, V.; Ainika Adamson, synlabee; Epp Sepp, synlabee; Tserel, L.; Kisand, K.; Peterson, P. Antibody Response after COVID-19 MRNA Vaccination in Relation to Age, Sex, and Side Effects. <https://doi.org/10.1101/2021.04.19.21255714>.
- [16] Pellini, R.; Venuti, A.; Pimpinelli, F.; Abril, E.; Blandino, G.; Campo, F.; Conti, L.; De Virgilio, A.; De Marco, F.; Di Domenico, E. G.; *et al.* Initial Observations on Age, Gender, BMI and Hypertension in Antibody Responses to SARS-CoV-2 BNT162b2 Vaccine. *EClinicalMedicine*, **2021**. <https://doi.org/10.1016/j.eclinm.2021.100928>.
- [17] Salvagno, G. L.; Henry, B. M.; Di Piazza, G.; Pighi, L.; De Nitto, S.; Bragantini, D.; Gianfilippi, G. L.; Lippi, G. Anti-Sars-Cov-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing Covid-19 Mrna Bnt162b2 Vaccination. *Diagnostics*, **2021**, *11* (5). <https://doi.org/10.3390/diagnostics11050832>.
- [18] Klein, S. L.; Flanagan, K. L. Sex Differences in Immune Responses. *Nat. Rev. Immunol.*, **2016**, *16* (10), 626–638. <https://doi.org/10.1038/nri.2016.90>.
- [19] Giefing-Kröll, C.; Berger, P.; Lepperdinger, G.; Grubeck-Loebenstien, B. How Sex and Age Affect Immune Responses, Susceptibility to Infections, and Response to Vaccination. *Aging Cell*, **2015**, *14* (3), 309–321. <https://doi.org/10.1111/accel.12326>.
- [20] Fischinger, S.; Boudreau, C. M.; Butler, A. L.; Streeck, H.; Alter, G. Sex Differences in Vaccine-Induced Humoral Immunity. *Semin. Immunopathol.*, **2019**, *41* (2), 239–249. <https://doi.org/10.1007/s00281-018-0726-5>.
- [21] Ciarambino, T.; *et al.*, Immune System and COVID-19 by Sex Differences and Age. *Womens. Health (Lond. Engl.)*, **2021**, *17*, 17455065211022262–17455065211022262. <https://doi.org/10.1177/17455065211022262>.
- [22] Ma, Q.; Hao, Z. W.; Wang, Y. F. The Effect of Estrogen in Coronavirus Disease 2019. *Am. J. Physiol. - Lung Cell. Mol. Physiol.*, **2021**, *321* (1), 219–227.

- <https://doi.org/10.1152/AJPLUNG.00332.2020>.
- [23] Manica, M.; Pancheri, S.; Poletti, P.; Giovanazzi, G.; Guzzetta, G.; Trentini, F.; Marziano, V.; Ajelli, M.; Grazia Zuccali, M.; Benetollo, P. P.; *et al.* Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2–Seropositive Individuals. *Clin. Infect. Dis.*, **2021**, 2019–2022. <https://doi.org/10.1093/cid/ciab556>.
- [24] Fraley, E.; LeMaster, C.; Geanes, E.; Banerjee, D.; Khanal, S.; Grundberg, E.; Selvarangan, R.; Bradley, T. Humoral Immune Responses during SARS-CoV-2 mRNA Vaccine Administration in Seropositive and Seronegative Individuals. *BMC Med.*, **2021**, *19* (1), 1–12. <https://doi.org/10.1186/s12916-021-02055-9>.
- [25] Favresse, J.; Bayart, J.-L.; Mullier, F.; Dogné, J.-M.; Closset, M.; Douxfils, J. Early Antibody Response in Health-Care Professionals after Two Doses of SARS-CoV-2 mRNA Vaccine (BNT162b2). *Clin. Microbiol. Infect.*, **2021**, *27* (9), 1351.e5. <https://doi.org/10.1016/J.CMI.2021.05.004>.
- [26] Callegaro, A.; Borleri, D.; Farina, C.; Napolitano, G.; Valenti, D.; Rizzi, M.; Maggiolo, F. Antibody Response to SARS-CoV-2 Vaccination Is Extremely Vivacious in Subjects with Previous SARS-CoV-2 Infection. *J. Med. Virol.*, **2021**, *93* (7), 4612–4615. <https://doi.org/10.1002/jmv.26982>.
- [27] Ebinger, J. E.; Fert-Bober, J.; Printsev, I.; Wu, M.; Sun, N.; Prostko, J. C.; Frias, E. C.; Stewart, J. L.; Van Eyk, J. E.; Braun, J. G.; *et al.* Antibody Responses to the BNT162b2 mRNA Vaccine in Individuals Previously Infected with SARS-CoV-2. *Nat. Med.*, **2021**, *27* (6), 981–984. <https://doi.org/10.1038/s41591-021-01325-6>.
- [28] Padoan, A.; Dall’Olmo, L.; Rocca, F. della; Barbaro, F.; Cosma, C.; Basso, D.; Cattelan, A.; Cianci, V.; Plebani, M. Antibody Response to First and Second Dose of BNT162b2 in a Cohort of Characterized Healthcare Workers. *Clin. Chim. Acta.*, **2021**, *519*, 60. <https://doi.org/10.1016/J.CCA.2021.04.006>.
- [29] Kelsen, S. G.; Braverman, A. S.; Aksoy, M. O.; Hayman, J. A.; Patel, P.; Rajput, C.; Zhao, H.; Fisher, S. G.; Ruggieri, M. R.; Gentile, N. T. A Longitudinal Study of BNT162b2 Vaccine-Induced Humoral Response and Reactogenicity in Health Care Workers with Prior COVID-19 Disease. *medRxiv*, **2021**, 2021.03.18.21253845. <https://doi.org/10.1101/2021.03.18.21253845>.
- [30] Demonbreun, A. R.; Sancilio, A.; Velez, M. E.; Ryan, D. T.; Saber, R.; Vaught, L. A.; Reiser, N. L.; Hsieh, R. R.; D’Aquila, R. T.; Mustanski, B.; *et al.* Comparison of IgG and Neutralizing Antibody Responses after One or Two Doses of COVID-19 mRNA Vaccine in Previously Infected and Uninfected Persons. *medRxiv*, **2020**, *6* (165), 1–13.
- [31] Yan, X.; Chen, G.; Jin, Z.; Zhang, Z.; Zhang, B.; He, J.; Yin, S.; Huang, J.; Fan, M.; Li, Z.; Chen, F. Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. *Journal of Medical Virology*. **2021**. <https://doi.org/10.1002/jmv.27274>.
- [32] Krammer, F.; Srivastava, K.; Team, P.; Simon, V.; Alshammary, H.; Amoako, A.; Awawda, M.; Beach, K.; Bermúdez-González, C. M.; Bialak, D.; *et al.* Robust Spike Antibody Responses and Increased Reactogenicity in Seropositive Individuals after a 1 Single Dose of SARS-CoV-2 mRNA Vaccine 2 3. *medRxiv*, **2021**, 2021.01.29.21250653.
- [33] Efrati, S.; Catalogna, M.; Abu Hamad, R.; Hadanny, A.; Bar-Chaim, A.; Benveniste-Levkovitz, P.; Levtzion-korach, O. Safety and Humoral Responses to BNT162b2 mRNA Vaccination of SARS-CoV-2 Previously Infected and Naive Populations. *Sci. Rep.*, **2021**, *11* (1), 1–13. <https://doi.org/10.1038/s41598-021-96129-6>.



- [34] Prendecki, M.; Clarke, C.; Brown, J.; Cox, A.; Gleeson, S.; Guckian, M.; Randell, P.; Dalla Pria, A.; Lightstone, L.; Xu, X.-N.; *et al.* Effect of Previous SARS-CoV-2 Infection on Humoral and T-Cell Responses to Single-Dose BNT162b2 Vaccine. **2021**. <https://doi.org/10.1101/2021>.
- [35] Sasso, B. Lo; Giglio, R. V.; Vidali, M.; Scazzino, C.; Bivona, G.; Gambino, C. M.; Ciaccio, A. M.; Agnello, L.; Ciaccio, M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 MRNA BNT162b2 Vaccine. *Diagnostics*, **2021**, *11* (7). <https://doi.org/10.3390/DIAGNOSTICS11071135>.
- [36] Yang, F.; Shi, S.; Zhu, J.; Shi, J.; Dai, K.; Chen, X. Analysis of 92 Deceased Patients with COVID-19. *J. Med. Virol.*, **2020**, *92* (11), 2511–2515. <https://doi.org/10.1002/jmv.25891>.
- [37] Dooley, K. E.; Chaisson, R. E. Tuberculosis and Diabetes Mellitus: Convergence of Two Epidemics. *Lancet Infect. Dis.*, **2009**, *9* (12), 737–746. [https://doi.org/10.1016/S1473-3099\(09\)70282-8](https://doi.org/10.1016/S1473-3099(09)70282-8).
- [38] Kwetkat, A.; Heppner, H. J. Comorbidities in the Elderly and Their Possible Influence on Vaccine Response. *Interdiscip. Top. Gerontol. Geriatr.*, **2020**, *43*, 73–85. <https://doi.org/10.1159/000504491>.
- [39] Emanuel, E. J.; Persad, G.; Upshur, R.; Thome, B.; Parker, M.; Glickman, A.; Zhang, C.; Boyle, C.; Smith, M.; Phillips, J. P. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *N. Engl. J. Med.*, **2020**, *382* (21), 2049–2055. <https://doi.org/10.1056/nejmsb2005114>.
- [40] Razzaghi, H.; Wang, Y.; Lu, H.; Marshall, K. E.; Dowling, N. F.; Paz-Bailey, G.; Twentyman, E. R.; Peacock, G.; Greenlund, K. J. Estimated County-Level Prevalence of Selected Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19 Illness — United States, 2018. *MMWR. Morb. Mortal. Wkly. Rep.*, **2020**, *69* (29), 945–950. <https://doi.org/10.15585/mmwr.mm6929a1>.
- [41] Kato, S.; Chmielewski, M.; Honda, H.; Pecoits-Filho, R.; Matsuo, S.; Yuzawa, Y.; Tranaeus, A.; Stenvinkel, P.; Lindholm, B. Aspects of Immune Dysfunction in End-Stage Renal Disease. *Clin. J. Am. Soc. Nephrol.*, **2008**, *3* (5), 1526–1533. <https://doi.org/10.2215/CJN.00950208>.
- [42] Windpessl, M.; Bruchfeld, A.; Anders, H. J.; Kramer, H.; Waldman, M.; Renia, L.; Ng, L. F. P.; Xing, Z.; Kronbichler, A. COVID-19 Vaccines and Kidney Disease. *Nat. Rev. Nephrol.*, **2021**, *17* (5), 291–293. <https://doi.org/10.1038/s41581-021-00406-6>.
- [43] Jahn, M.; Korth, J.; Dorsch, O.; Anastasiou, O. E.; Sorge-Hädicke, B.; Tyczynski, B.; Gäckler, A.; Witzke, O.; Dittmer, U.; Dolff, S.; *et al.* Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-Biontech) in Patients on Hemodialysis. *Vaccines*, **2021**, *9* (4), 1–8. <https://doi.org/10.3390/vaccines9040360>.
- [44] Goupil, R.; Benlarbi, M.; Beaubien-Souligny, W.; Nadeau-Fredette, A. C.; Chatterjee, D.; Goyette, G.; Gunaratnam, L.; Lamarche, C.; Tom, A.; Finzi, A.; *et al.* Short-Term Antibody Response after 1 Dose of BNT162b2 Vaccine in Patients Receiving Hemodialysis. *Cmaj*, **2021**, *193* (22), E793–E800. <https://doi.org/10.1503/cmaj.210673>.
- [45] Frantzen, L.; Cavallé, G.; Thibeaut, S.; El-Haik, Y. Efficacy of the BNT162b2 MRNA COVID-19 Vaccine in a Haemodialysis Cohort. *Nephrol. Dial. Transplant.*, **2021**, *36* (9), 1756–1757. <https://doi.org/10.1093/ndt/gfab165>.
- [46] Torreggiani, M.; Bianchi, S.; Fois, A.; Fessi, H.; Piccoli, G. B. Neutralizing SARS-CoV-2 Antibody Response in Dialysis Patients after the First Dose of the BNT162b2 MRNA COVID-19 Vaccine: The War Is Far from Being Won. *Kidney Int.*, **2021**, *99* (6), 1494.

- <https://doi.org/10.1016/J.KINT.2021.04.010>.
- [47] Mulley, W. R.; Dendle, C.; Ling, J. E. H.; Knight, S. R. Does Vaccination in Solid-Organ Transplant Recipients Result in Adverse Immunologic Sequelae? A Systematic Review and Meta-Analysis. *J. Hear. Lung Transplant.*, **2018**, *37* (7), 844–852. <https://doi.org/10.1016/j.healun.2018.03.001>.
- [48] Katerinis, I.; Hadaya, K.; Duquesnoy, R.; Ferrari-Lacraz, S.; Meier, S.; Van Delden, C.; Martin, P. Y.; Siegrist, C. A.; Villard, J. De Novo Anti-HLA Antibody after Pandemic H1N1 and Seasonal Influenza Immunization in Kidney Transplant Recipients. *Am. J. Transplant.*, **2011**, *11* (8), 1727–1733. <https://doi.org/10.1111/j.1600-6143.2011.03604.x>.
- [49] Schaffer, S. A.; Husain, S.; Delgado, D. H.; Kavanaugh, L.; Ross, H. J. Impact of Adjuvanted H1N1 Vaccine on Cell-Mediated Rejection in Heart Transplant Recipients. *Am. J. Transplant.*, **2011**, *11* (12), 2751–2754. <https://doi.org/10.1111/j.1600-6143.2011.03743.x>.
- [50] Danziger-isakov, L.; Cherkassky, L.; Siegel, H.; Mcmanamon, M.; Kramer, K.; Budev, M.; Sawinski, D.; Augustine, J. J.; Hricik, D. E.; Fairchild, R.; *et al.* NIH Public Access. **2013**, *89* (7), 838–844. <https://doi.org/10.1097/TP.0b013e3181ca56f8.Effects>.
- [51] Kumar, D.; Blumberg, E. A.; Danziger-Isakov, L.; Kotton, C. N.; Halasa, N. B.; Ison, M. G.; Avery, R. K.; Green, M.; Allen, U. D.; Edwards, K. M.; *et al.* Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations. *Am. J. Transplant.*, **2011**, *11* (10), 2020–2030. <https://doi.org/10.1111/j.1600-6143.2011.03753.x>.
- [52] Pereira, M. R.; Mohan, S.; Cohen, D. J.; Husain, S. A.; Dube, G. K.; Ratner, L. E.; Arcasoy, S.; Aversa, M. M.; Benvenuto, L. J.; Dadhania, D. M.; *et al.* COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter. *Am. J. Transplant.*, **2020**, *20* (7), 1800–1808. <https://doi.org/10.1111/ajt.15941>.
- [53] Aslam, S.; Goldstein, D. R.; Vos, R.; Gelman, A. E.; Kittleson, M. M.; Wolfe, C.; Danziger-Isakov, L. COVID-19 Vaccination in Our Transplant Recipients: The Time Is Now. *J. Hear. Lung Transplant.*, **2021**, *40* (3), 169–171. <https://doi.org/10.1016/j.healun.2020.12.009>.
- [54] Marinaki, S.; Adamopoulos, S.; Degiannis, D.; Roussos, S.; Pavlopoulou, I. D.; Hatzakis, A.; Boletis, I. N. Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients. *Am. J. Transplant.*, **2021**, *21* (8), 2913–2915. <https://doi.org/10.1111/ajt.16607>.
- [55] Shostak, Y.; Shafran, N.; Heching, M.; Rosengarten, D.; Shtraichman, O.; Shitenberg, D.; Amor, S. M.; Yahav, D.; Ben Zvi, H.; Pertzov, B.; *et al.* Early Humoral Response among Lung Transplant Recipients Vaccinated with BNT162b2 Vaccine. *Lancet Respir. Med.*, **2021**, *9* (6), e52–e53. [https://doi.org/10.1016/S2213-2600\(21\)00184-3](https://doi.org/10.1016/S2213-2600(21)00184-3).
- [56] Grupper, A.; Rabinowich, L.; Schwartz, D.; Schwartz, I. F.; Ben-Yehoyada, M.; Shashar, M.; Katchman, E.; Halperin, T.; Turner, D.; Goykhman, Y.; *et al.* Reduced Humoral Response to MRNA SARS-CoV-2 BNT162b2 Vaccine in Kidney Transplant Recipients without Prior Exposure to the Virus. *Am. J. Transplant.*, **2021**, *21* (8), 2719–2726. <https://doi.org/10.1111/ajt.16615>.
- [57] Korth, J.; Jahn, M.; Dorsch, O.; Anastasiou, O. E.; Sorge-Hädicke, B.; Eisenberger, U.; Gäckler, A.; Dittmer, U.; Witzke, O.; Wilde, B.; *et al.* Impaired Humoral Response in Renal Transplant Recipients to Sars-Cov-2 Vaccination with Bnt162b2 (Pfizer-Biontech). *Viruses*, **2021**, *13* (5), 4–9. <https://doi.org/10.3390/v13050756>.
- [58] Hiam-Galvez, K. J.; Allen, B. M.; Spitzer, M. H. Systemic Immunity in Cancer. *Nat. Rev. Cancer*, **2021**, *21* (6), 345–359. <https://doi.org/10.1038/s41568-021-00347-z>.

- [59] Gonzalez, H.; Hagerling, C.; Werb, Z. Roles of the Immune System in Cancer: From Tumor Initiation to Metastatic Progression. *Genes Dev.*, **2018**, *32* (19–20), 1267–1284. <https://doi.org/10.1101/GAD.314617.118>.
- [60] Looi, C. K.; Chung, F. F. L.; Leong, C. O.; Wong, S. F.; Rosli, R.; Mai, C. W. Therapeutic Challenges and Current Immunomodulatory Strategies in Targeting the Immunosuppressive Pancreatic Tumor Microenvironment. *J. Exp. Clin. Cancer Res.*, **2019**, *38* (1), 1–23. <https://doi.org/10.1186/s13046-019-1153-8>.
- [61] Esperança-Martins, M.; Gonçalves, L.; Soares-Pinho, I.; Gomes, A.; Serrano, M.; Blankenhaus, B.; Figueiredo-Campos, P.; Catarina-Marques, A.; Castro-Barbosa, A.; Cardoso, A.; *et al.* Humoral Immune Response of SARS-CoV-2–Infected Patients with Cancer: Influencing Factors and Mechanisms. *Oncologist*, **2021**, *26* (9), e1619–e1632. <https://doi.org/10.1002/onco.13828>.
- [62] Meerveld-Eggink, A.; de Weerd, O.; van der Velden, A. M. T.; Los, M.; van der Velden, A. W. G.; Stouthard, J. M. L.; Nijziel, M. R.; Westerman, M.; Beeker, A.; van Beek, R.; *et al.* Response to Influenza Virus Vaccination during Chemotherapy in Patients with Breast Cancer. *Ann. Oncol.*, **2011**, *22* (9), 2031–2035. <https://doi.org/10.1093/annonc/mdq728>.
- [63] Herishanu, Y.; Avivi, I.; Aharon, A.; Shefer, G.; Levi, S.; Bronstein, Y.; Morales, M.; Ziv, T.; Arbel, Y. S.; Scarfò, L.; *et al.* Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2021**, *137* (23), 3165. <https://doi.org/10.1182/BLOOD.2021011568>.
- [64] Massarweh, A.; Eliakim-Raz, N.; Stemmer, A.; Levy-Barda, A.; Yust-Katz, S.; Zer, A.; Benouaich-Amiel, A.; Ben-Zvi, H.; Moskovits, N.; Brenner, B.; *et al.* Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. *JAMA Oncol.*, **2021**, *7* (8), 1. <https://doi.org/10.1001/JAMAONCOL.2021.2155>.
- [65] Pimpinelli, F.; Marchesi, F.; Piaggio, G.; Giannarelli, D.; Papa, E.; Falcucci, P.; Pontone, M.; Di Martino, S.; Laquintana, V.; La Malfa, A.; *et al.* Fifth-Week Immunogenicity and Safety of Anti-SARS-CoV-2 BNT162b2 Vaccine in Patients with Multiple Myeloma and Myeloproliferative Malignancies on Active Treatment: Preliminary Data from a Single Institution. *J. Hematol. Oncol.*, **2021**, *14* (1), 1–12. <https://doi.org/10.1186/s13045-021-01090-6>.
- [66] Goshen-Lago, T.; Waldhorn, I.; Holland, R.; Szwarcwort-Cohen, M.; Reiner-Benaim, A.; Shachor-Meyouhas, Y.; Hussein, K.; Fahoum, L.; Baruch, M.; Peer, A.; *et al.* Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. *JAMA Oncol.*, **2021**. <https://doi.org/10.1001/jamaoncol.2021.2675>.
- [67] Wang, L.; Wang, F. S.; Gershwin, M. E. Human Autoimmune Diseases: A Comprehensive Update. *J. Intern. Med.*, **2015**, *278* (4), 369–395. <https://doi.org/10.1111/joim.12395>.
- [68] Lerner, A.; Jeremias, P.; Matthias, T. The World Incidence and Prevalence of Autoimmune Diseases Is Increasing. *Int. J. Celiac Dis.*, **2015**, *3* (4), 151–155. <https://doi.org/10.12691/ijcd-3-4-8>.
- [69] Gallo, A.; Capuano, R.; Donnarumma, G.; Biseco, A.; Grimaldi, E.; Conte, M.; d’Ambrosio, A.; Coppola, N.; Galdiero, M.; Tedeschi, G. Preliminary Evidence of Blunted Humoral Response to SARS-CoV-2 mRNA Vaccine in Multiple Sclerosis Patients Treated with Ocrelizumab. *Neurol. Sci.*, **2021**, *42* (9), 3523–3526. <https://doi.org/10.1007/s10072-021-05397-7>.
- [70] Furer, V.; Eviatar, T.; Zisman, D.; Peleg, H.; Paran, D.; Levartovsky, D.; Zisapel, M.;

- Elalouf, O.; Kaufman, I.; Meidan, R.; *et al.* Immunogenicity and Safety of the BNT162b2 MRNA COVID-19 Vaccine in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and in the General Population: A Multicentre Study. *Ann. Rheum. Dis.*, **2021**, 1–9. <https://doi.org/10.1136/annrheumdis-2021-220647>.
- [71] Andersen, C. J.; Murphy, K. E.; Fernandez, M. L. Impact of Obesity and Metabolic Syndrome on Immunity. *Adv. Nutr.*, **2016**, *7* (1), 66–75. <https://doi.org/10.3945/an.115.010207>.
- [72] Sheridan, P. A.; Paich, H. A.; Handy, J.; Karlsson, E. A.; Hudgens, M. G.; Sammon, A. B.; Holland, L. A.; Weir, S.; Noah, T. L.; Beck, M. A. Obesity Is Associated with Impaired Immune Response to Influenza Vaccination in Humans. *Int. J. Obes.*, **2012**, *36* (8), 1072–1077. <https://doi.org/10.1038/ijo.2011.208>.
- [73] Watanabe, M.; Balena, A.; Tuccinardi, D.; Tozzi, R.; Risi, R.; Masi, D.; Caputi, A.; Rossetti, R.; Spoltore, M. E.; Filippi, V.; *et al.* Central Obesity, Smoking Habit, and Hypertension Are Associated with Lower Antibody Titres in Response to COVID-19 MRNA Vaccine. *Diabetes. Metab. Res. Rev.*, **2021**, No. April. <https://doi.org/10.1002/dmrr.3465>.
- [74] Francisco, V.; Pino, J.; Campos-Cabaleiro, V.; Ruiz-Fernández, C.; Mera, A.; Gonzalez-Gay, M. A.; Gómez, R.; Gualillo, O. Obesity, Fat Mass and Immune System: Role for Leptin. *Front. Physiol.*, **2018**, *9* (JUN), 1–20. <https://doi.org/10.3389/fphys.2018.00640>.
- [75] Tanaka, M.; Itoh, H. Hypertension as a Metabolic Disorder and the Novel Role of the Gut. *Curr. Hypertens. Rep.*, **2019**, *21* (8). <https://doi.org/10.1007/s11906-019-0964-5>.
- [76] Singh, M. V.; Chapleau, M. W.; Harwani, S. C.; Abboud, F. M. The Immune System and Hypertension. *Immunol. Res.*, **2014**, *59* (1–3), 243–253. <https://doi.org/10.1007/s12026-014-8548-6>.
- [77] Qiu, F.; Liang, C. L.; Liu, H.; Zeng, Y. Q.; Hou, S.; Huang, S.; Lai, X.; Dai, Z. Impacts of Cigarette Smoking on Immune Responsiveness: Up and down or Upside Down? *Oncotarget*, **2017**, *8* (1), 268–284. <https://doi.org/10.18632/oncotarget.13613>.
- [78] Zitt, E.; Davidovic, T.; Schimpf, J.; Abbassi-Nik, A.; Mutschlechner, B.; Ulmer, H.; Benda, M. A.; Sprenger-Mähr, H.; Winder, T.; Lhotta, K. The Safety and Immunogenicity of the MRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. *Front. Immunol.*, **2021**, *12*, 1. <https://doi.org/10.3389/FIMMU.2021.704773>.
- [79] Flaxman, A.; Marchevsky, N. G.; Jenkin, D.; Aboagye, J.; Aley, P. K.; Angus, B.; Belij-Rammerstorfer, S.; Bibi, S.; Bittaye, M.; Cappuccini, F.; *et al.* Oxford COVID Vaccine Trial group. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet*. **2021**, *398* (10304), 981-990. [https://doi.org/10.1016/S0140-6736\(21\)01699-8](https://doi.org/10.1016/S0140-6736(21)01699-8).
- [80] Falsey, A. R.; Frenck, R. W. Jr; Walsh, E. E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Bailey, R.; Swanson, K. A.; Xu X.; *et al.* SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med*. **2021**. <https://doi.org/10.1056/NEJMc2113468>.
- [81] Werbel, W. A.; Boyarsky, B. J.; Ou, M. T.; Massie, A. B.; Tobian, A. A. R.; Garonzik-Wang, J. M.; Segev, D. L. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. *Ann Intern Med*. **2021**, *174* (9), 1330-1332. <https://doi.org/10.7326/L21-0282>.
- [82] Bensouna, I.; Caudwell, V.; Kubab, S.; Acquaviva, S.; Pardon, A.; Vittoz, N.; Bozman, D. F.; Hanafi, L.; Faucon, A. L.; Housset, P. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or

- Peritoneal Dialysis. *Am J Kidney Dis.* **2021.** S0272-6386(21)00833-7.  
<https://doi.org/10.1053/j.ajkd.2021.08.005>.
- [83] Choi, A.; Koch, M.; Wu, K.; Chu, L.; Ma, L.; Hill, A.; Nunna, N.; Huang, W.; Oestreicher, J.; Colpitts, T.; *et al.* Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med.* **2021.**  
<https://doi.org/10.1038/s41591-021-01527-y>.
- [84] Lippi, G.; Henry B. M.; Plebani M. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?. *Clin Chem Lab Med.* **2021.**  
<https://doi.org/10.1515/cclm-2021-0972>.